Washington, DC
May 20–21, 2019
Seating is limited.
Confirmed speakers and schedule to date:
Monday, May 20
1:10–1:50 pm
- Abby Alpert, University of Pennsylvania
How Does Incremental Innovation Respond to Competition? Evidence from Biologic Drugs
1:50–2:30 pm
- Annabelle Fowler, Harvard University
Unintended Consequences of Regulation: Strategic Line Extension Entry
2:45–3:25 pm
- Margaret Kyle, MINES Paris Tech
Entry Agreements and Generic Drug Competition in Europe
3:25–4:05 pm
- Sharat Ganapati, Georgetown University
Non-Tariff Barriers and Bargaining in Generic Pharmaceuticals
6:30–8:30 pm
- Tomas Philipson, Council of Economic Advisers
Keynote speech
Tuesday, May 21
9:35–10:15 am
- Chirantan Chatterjee, Hoover Institution
Moving Beyond the Valley of Death: Regulation and Venture Capital Investments in Early-Stage Biopharmaceutical Firms
10:15–10:55 am
- Amber Jessup, US Department of Health and Human Services
How Can We Improve Efficiency of Clinical Trials?
11:10–11:50 am
- Pinar Karaca-Mandic, University of Minnesota
Medical Reversals: Understanding De-adoption of Ineffective or Unsafe Treatments
11:50 am–12:30 pm
- Ruben Jacobo-Rubio, US Food and Drug Administration
Patent Challenges, Generic Entry, and Follow-on Pharmaceutical Innovation: Testing Strategic Investments in Product Proliferation
1:30–2:10 pm
- Kosali Simon, Indiana University
Impacts of Expansion of Public Health Insurance on Drug Marketing
2:10–2:50 pm
- Pierre Dubois, Toulouse School of Economics
Bargaining and International Reference Pricing in the Pharmaceutical Industry
2:50–3:30 pm
- Frank Lichtenberg, Columbia University
Creative Destruction: The Effect of New Drug Entry on Old Drug Prices in the US, 2010–2016
For more information, please contact Lucinda Lanier.
